Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Adakitug by Bristol-Myers Squibb for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hormone-Sensitive Prostate Cancer. According to GlobalData,...
Adakitug by Bristol-Myers Squibb for Human Papillomavirus (HPV) Associated Cancer: Likelihood of Approval
Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer. According...
Adakitug by Bristol-Myers Squibb for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to...
Adakitug by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Adakitug by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Adakitug?
Adakitug is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Solid Tumor. According to...
Adakitug by Bristol-Myers Squibb for Renal Cell Carcinoma: Likelihood of Approval
Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase I for Renal Cell Carcinoma. According to GlobalData,...